← Back
Data updated: Mar 10, 2026
SOLVAY
CardiovascularGastroenterology
SOLVAY is a specialty pharmaceutical company focused on Cardiovascular, Gastroenterology.
1965
Since
45
Drugs
-
Trials
16
Approved (2yr)
Key Drugs
No active drugs
Recent Activity
PYRIDOSTIGMINE BROMIDE 2025-09-26
Labeling
METHOCARBAMOL 2025-04-08
Labeling
LACTULOSE 2025-03-14
LACTULOSE 2024-12-13
PYRIDOSTIGMINE BROMIDE 2024-10-04
Manufacturing (CMC)
PYRIDOSTIGMINE BROMIDE 2024-10-04
Type 5 - New Formulation or New Manufacturer
HYDROCHLOROTHIAZIDE 2024-09-19
Manufacturing (CMC)
LACTULOSE 2024-09-17
Manufacturing (CMC)
HYDROCHLOROTHIAZIDE 2024-08-22
Labeling
PHENDIMETRAZINE TARTRATE 2024-08-02
Manufacturing (CMC)
SEC Filings
Pro
Loading...
Therapeutic Focus
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Cardiovascular 50%
1 drugs
Gastroenterology 50%
1 drugs
Pipeline Strength Pro
Loading...
Active (1)
Discontinued (44)
PYRIDOSTIGMINE BROMIDE METHOCARBAMOL LACTULOSE PHENDIMETRAZINE TARTRATE LUVOX RESERPINE, HYDRALAZINE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE RESERPINE MEPROBAMATE ESTRATAB DEXONE 1.5 BUTABARBITAL SODIUM LITHONATE LITHOTABS CURRETAB DERMACORT HYDRALAZINE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE ARESTOCAINE HYDROCHLORIDE W/ LEVONORDEFRIN BALNEOL-HC ZIDE TORA ARESTOCAINE HYDROCHLORIDE ESTRAGUARD TRANMEP S.A.S.-500 ORASONE RAUWOLFIA SERPENTINA SULSOXIN AQUATAG CIN-QUIN TRIACORT PORTALAC PROVAL #3 GYNOREST DEXONE 0.75 UNIPRES RETET SER-A-GEN R-P MYCIN DUPHALAC DEXONE 0.5 DEXONE 4 SPRX-3 VERMIDOL SYMADINE
Company Info
- First Approval
- 1965-08-17
- Latest
- 2001-09-06
- Applications
- 63